Neostigmine (Bromide)

Neostigmine (Eustigmin) Bromide is an orally active and reversible cholinesterase inhibitor that acts on myasthenia gravis to prolong and intensify the muscarinic and nicotinic effects of acetylcholine. Neostigmine Bromide can be used in anesthesia to reverse the neuromuscular blockade produced by competitive neuromuscular blockers[1][2][3][4].

Product Specifications

CAS Number

[114-80-7]

Product Name Alternative

Eustigmin bromide; Neoserine bromide

UNSPSC

12352005

Hazard Statement

H300+H310+H330, H315, H317, H319, H334, H335

Target

Cholinesterase (ChE)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/neostigmine-bromide.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

C[N+](C)(C)C1=CC=CC(OC(N(C)C)=O)=C1.[Br-]

Molecular Formula

C12H19BrN2O2

Molecular Weight

303.20

Precautions

H300+H310+H330, H315, H317, H319, H334, H335

References & Citations

[1]Nanjwade B K, et al. Development and evaluation of intranasal mucoadhesive microspheres of neostigmine bromide[J]. Pharm Anal Acta, 2011, 2 (2) : 1-6.|[2]Khorshid AF, et al. Modified carbon paste sensor for the potentiometric determination of neostigmine bromide in pharmaceutical formulations, human plasma and urine. Biosens Bioelectron. 2014 Jan 15;51:143-9. |[3]SCHWAB RS, et al. Treatment of myasthenia gravis; prolonged action with multiple-dose tablets of neostigmine bromide and mestinon bromide. J Am Med Assoc. 1957 Oct 12;165 (6) :671-4.|[4]Makkar R, et al. Development and validation of a stability-indicating method for neostigmine bromide: separation, identification and characterization of degradation product using LC-MS and ESI-Q-TOF-MS/MS[J]. Indian Journal of Pharmaceutical Sciences, 2022, 56: 1-13.